Track Samrat Pharmachem Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 1.38 %
Low
246.0
High
263.0
1 Month returns: 29.82 %
Low
195.7
High
296.0
1 Year returns: -32.06 %
Low
190.0
High
377.8
3 Year CAGR: -18.23 %
Low
190.0
High
646.0
5 Year CAGR: -0.27 %
Low
170.0
High
1,250.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Samrat Pharmachem Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Samrat Pharmachem Ltd. Shareholding Pattern
Quarterly breakdown of Samrat Pharmachem Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Samrat Pharmachem Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Samrat Pharmachem Ltd.?
The current share price of Samrat Pharmachem Ltd. is ₹ 257.50 as of 17 Jul 2026.
What is the market capitalisation of Samrat Pharmachem Ltd.?
The market capitalisation of Samrat Pharmachem Ltd. stands at ₹ 79.57 Cr.
What is the PE ratio of Samrat Pharmachem Ltd.?
The Price-to-Earnings (PE) ratio of Samrat Pharmachem Ltd. is - as of the latest trailing twelve months data.
What is the ROE and ROCE of Samrat Pharmachem Ltd.?
Samrat Pharmachem Ltd. has a Return on Equity (ROE) of -4.73% and a Return on Capital Employed (ROCE) of -3.56% as per the latest financial reports.
What is the 52-week high and low of Samrat Pharmachem Ltd.?
The 52-week high of Samrat Pharmachem Ltd. is - and the 52-week low is -.
What is the dividend yield of Samrat Pharmachem Ltd.?
The dividend yield of Samrat Pharmachem Ltd. is 0.39% based on the current market price.
What is the FII and DII holding in Samrat Pharmachem Ltd.?
Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 44.91% of Samrat Pharmachem Ltd. shares.
What sector does Samrat Pharmachem Ltd. belong to?
Samrat Pharmachem Ltd. operates in the Healthcare sector.
What is the beta of Samrat Pharmachem Ltd.?
The beta of Samrat Pharmachem Ltd. is 0.77, indicating its price volatility relative to the broader market. Over the past 1 year, Samrat Pharmachem Ltd. has delivered an absolute return of -31.90%.
What is the RSI of Samrat Pharmachem Ltd.?
The 14-day Relative Strength Index (RSI) of Samrat Pharmachem Ltd. is 60.33, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Samrat Pharmachem Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.16 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.02 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 3 financial years
What is Dividend streak?
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Earnings yield of -4.16% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis
What is Earnings yield (E/P)?
Low and declining ROE
The company reported low ROE of -4.73% for 12-month ended 31 Mar 2026 and ROE declined by -1513 bps from 1 year ago
What is ROE (FY)?
Low and declining operating margin
The company reported low operating margin of -0.99% for 12-month ended 31 Mar 2026 and operating margin declined by -434 bps from 1 year ago
What is Operating profit margin?
Low revenue growth and lower than median growth of industry
The company delivered moderate revenue growth of 1.35% for 12-month ended 31 Mar 2026 and the growth was 9.88 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 11.23
Value 1.35
-82.35114662
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -146.57% for 12-month ended 31 Mar 2026 and the growth was 154.69 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.39%
What is Dividend yield?
Neutral
Not enough talking points with neutral stance
Thinly traded (low daily turnover)
The stock is thinly traded with combined (NSE & BSE) daily turnover (21-day average) of 0.109309.
Company Profile
Overview of Samrat Pharmachem Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Samrat Pharmachem Limited is an India-based manufacturer of iodine salts. The Company is engaged in the business of pharmaceutical chemicals. Its products include 3-5 Di Iodosalicylic Acid, Ammonium Iodide, Cadmium Iodide, Calcium Iodate, Clioquinol, Copper Iodide, Ethyl Iodide, Ethylenediamine Dihydroiodide, Hydroiodic Acid 57%, Iodine, Iodine Monochloride, Iodine Monochloride, Iodoquinol, Methyl Iodide, N-Iodo Succinimide, Periodic Acid, Potassium Iodate, Potassium Iodide, Potassium Metaper Iodate, Povidone Iodine, Selenium Dioxide, Sodium Iodate, Sodium Iodide, Sodium Metaper Iodate. These products are offered for the agrochemical, animal feed, chemical, cosmetics, food, pharmaceutical, painting and textile industries. The Company exports its products to geographics such as the United States, Europe, Africa, Asia, the Middle East and others.
Samrat Pharmachem Limited is an India-based manufacturer of iodine salts. The Company is engaged in the business of pharmaceutical chemicals. Its products include 3-5 Di Iodosalicylic Acid, Ammonium Iodide, Cadmium Iodide, Calcium Iodate, Clioquinol, Copper Iodide, Ethyl Iodide, Ethylenediamine Dihy...
Key personnel
Mr. Nishant Kumar Kankaria
Compliance Officer, Company Secretary
Mr. Lalit Damodar MehtaD
Executive Chairman of the Board, Managing Director